Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma
ObjectiveThe purpose of this study was to explore the clinical characteristics, survival time and prognostic factors of patients undergoing craniotomy for brain metastases (BM) from lung adenocarcinoma (LUAD).MethodsA total of 208 patients with BM from LUAD who underwent craniotomy at the Zhengzhou...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1453177/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592400483090432 |
|---|---|
| author | Ming Li Zhiying Li Hang Zhang Hiroaki Wakimoto Linlin Sun Tiantian Wang Shengli Zhou Liyun Zhou |
| author_facet | Ming Li Zhiying Li Hang Zhang Hiroaki Wakimoto Linlin Sun Tiantian Wang Shengli Zhou Liyun Zhou |
| author_sort | Ming Li |
| collection | DOAJ |
| description | ObjectiveThe purpose of this study was to explore the clinical characteristics, survival time and prognostic factors of patients undergoing craniotomy for brain metastases (BM) from lung adenocarcinoma (LUAD).MethodsA total of 208 patients with BM from LUAD who underwent craniotomy at the Zhengzhou University People’s Hospital, Henan province, China from March 2005 to October 2022 were included in this retrospective study. All patients were confirmed as BM of LUAD by histopathology. The clinical data included patient gender, age, occupation, family history of tumor, smoking history, alcohol drinking history, neurological symptoms, history of lung cancer treatment, tumor location, tumor number, tumor size, gene status, expression of S-100, CEA, Ki67, and PD-L1 by immunohistochemistry, KPS after craniotomy, whether tumor therapy was continued after craniotomy, and survival time. Univariate and multivariate Cox regression was used to analyze the prognostic factors of patients undergoing craniotomy for LUAD BM.ResultsA total of 208 patients met the inclusion and exclusion criteria, including 110 males (52.9%) and 98 females (47.1%), with an average age of 61.4 years. 203 patients (97.6%) had neurological symptoms. 84 patients (40.4%) had smoking history, 89 patients (42.8%) had alcohol drinking history, and 31 patients (14.9%) had the family history of tumor. Only 5 patients (2.4%) had received lung cancer treatment before craniotomy. The intracranial location of BM was mostly in the frontal lobe (54, 26.0%) and the metastatic sites were mostly single (117, 56.3%); the metastatic tumor size was mostly between 2-5 cm (141, 67.8%). Genetically, 43.3% patients (90 cases) had EGFR mutations, and immunohistochemical analysis showed that most patients were PD-L1 positive (160, 76.9%) and Ki67 > 30% (137, 65.9%). Most patients (145, 69.7%) had KPS score under 80 after craniotomy. Only 72 patients (34.7%) received continued tumor therapy after craniotomy. 190 patients (91.3%) were successfully followed up. The median survival time was 11.5 months, and the 3-year survival rate was 15.7%. Multivariate analysis revealed that smoking history, Ki67 percentage, KPS after craniotomy, and molecular targeted therapy after craniotomy were independent factors affecting the survival time of patients.ConclusionsAlthough survival remains poor, patients who had no-smoking history, Ki67 percentage ≤30%, KPS≥80 after craniotomy, and molecular targeted therapy after craniotomy can improve the prognosis and prolong the survival time. |
| format | Article |
| id | doaj-art-19208b07fe5c4a6b8fc4a54f94dc9974 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-19208b07fe5c4a6b8fc4a54f94dc99742025-01-21T08:36:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14531771453177Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinomaMing Li0Zhiying Li1Hang Zhang2Hiroaki Wakimoto3Linlin Sun4Tiantian Wang5Shengli Zhou6Liyun Zhou7Department of Neurosurgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, ChinaDepartment of Neurosurgery, The 7th People's Hospital of Zhengzhou, Zhengzhou, ChinaDepartment of Neurosurgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, ChinaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Neurosurgery, The 7th People's Hospital of Zhengzhou, Zhengzhou, ChinaDepartment of Neurology, The 7th People's Hospital of Zhengzhou, Zhengzhou, ChinaDepartment of Pathology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, ChinaDepartment of Neurosurgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, ChinaObjectiveThe purpose of this study was to explore the clinical characteristics, survival time and prognostic factors of patients undergoing craniotomy for brain metastases (BM) from lung adenocarcinoma (LUAD).MethodsA total of 208 patients with BM from LUAD who underwent craniotomy at the Zhengzhou University People’s Hospital, Henan province, China from March 2005 to October 2022 were included in this retrospective study. All patients were confirmed as BM of LUAD by histopathology. The clinical data included patient gender, age, occupation, family history of tumor, smoking history, alcohol drinking history, neurological symptoms, history of lung cancer treatment, tumor location, tumor number, tumor size, gene status, expression of S-100, CEA, Ki67, and PD-L1 by immunohistochemistry, KPS after craniotomy, whether tumor therapy was continued after craniotomy, and survival time. Univariate and multivariate Cox regression was used to analyze the prognostic factors of patients undergoing craniotomy for LUAD BM.ResultsA total of 208 patients met the inclusion and exclusion criteria, including 110 males (52.9%) and 98 females (47.1%), with an average age of 61.4 years. 203 patients (97.6%) had neurological symptoms. 84 patients (40.4%) had smoking history, 89 patients (42.8%) had alcohol drinking history, and 31 patients (14.9%) had the family history of tumor. Only 5 patients (2.4%) had received lung cancer treatment before craniotomy. The intracranial location of BM was mostly in the frontal lobe (54, 26.0%) and the metastatic sites were mostly single (117, 56.3%); the metastatic tumor size was mostly between 2-5 cm (141, 67.8%). Genetically, 43.3% patients (90 cases) had EGFR mutations, and immunohistochemical analysis showed that most patients were PD-L1 positive (160, 76.9%) and Ki67 > 30% (137, 65.9%). Most patients (145, 69.7%) had KPS score under 80 after craniotomy. Only 72 patients (34.7%) received continued tumor therapy after craniotomy. 190 patients (91.3%) were successfully followed up. The median survival time was 11.5 months, and the 3-year survival rate was 15.7%. Multivariate analysis revealed that smoking history, Ki67 percentage, KPS after craniotomy, and molecular targeted therapy after craniotomy were independent factors affecting the survival time of patients.ConclusionsAlthough survival remains poor, patients who had no-smoking history, Ki67 percentage ≤30%, KPS≥80 after craniotomy, and molecular targeted therapy after craniotomy can improve the prognosis and prolong the survival time.https://www.frontiersin.org/articles/10.3389/fonc.2024.1453177/fulllung adenocarcinoma brain metastasescraniotomyclinical characteristicssurvival timeprognostic factor |
| spellingShingle | Ming Li Zhiying Li Hang Zhang Hiroaki Wakimoto Linlin Sun Tiantian Wang Shengli Zhou Liyun Zhou Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma Frontiers in Oncology lung adenocarcinoma brain metastases craniotomy clinical characteristics survival time prognostic factor |
| title | Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| title_full | Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| title_fullStr | Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| title_full_unstemmed | Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| title_short | Clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| title_sort | clinical characteristics and outcomes of surgical resection for brain metastases from lung adenocarcinoma |
| topic | lung adenocarcinoma brain metastases craniotomy clinical characteristics survival time prognostic factor |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1453177/full |
| work_keys_str_mv | AT mingli clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT zhiyingli clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT hangzhang clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT hiroakiwakimoto clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT linlinsun clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT tiantianwang clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT shenglizhou clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma AT liyunzhou clinicalcharacteristicsandoutcomesofsurgicalresectionforbrainmetastasesfromlungadenocarcinoma |